Literature DB >> 24713617

Evidence-based pharmacological treatment of anxiety disorders, post-traumatic stress disorder and obsessive-compulsive disorder: a revision of the 2005 guidelines from the British Association for Psychopharmacology.

David S Baldwin1, Ian M Anderson, David J Nutt, Christer Allgulander, Borwin Bandelow, Johan A den Boer, David M Christmas, Simon Davies, Naomi Fineberg, Nicky Lidbetter, Andrea Malizia, Paul McCrone, Daniel Nabarro, Catherine O'Neill, Jan Scott, Nic van der Wee, Hans-Ulrich Wittchen.   

Abstract

This revision of the 2005 British Association for Psychopharmacology guidelines for the evidence-based pharmacological treatment of anxiety disorders provides an update on key steps in diagnosis and clinical management, including recognition, acute treatment, longer-term treatment, combination treatment, and further approaches for patients who have not responded to first-line interventions. A consensus meeting involving international experts in anxiety disorders reviewed the main subject areas and considered the strength of supporting evidence and its clinical implications. The guidelines are based on available evidence, were constructed after extensive feedback from participants, and are presented as recommendations to aid clinical decision-making in primary, secondary and tertiary medical care. They may also serve as a source of information for patients, their carers, and medicines management and formulary committees.

Entities:  

Keywords:  Anticonvulsants; antidepressants; antipsychotics; anxiety disorders; anxiolytics; benzodiazepines; cognitive behaviour therapy; evidence-based guidelines; generalised anxiety disorder; obsessive-compulsive disorder; panic disorder; post-traumatic stress disorder; pregabalin; selective serotonin reuptake inhibitor; separation anxiety disorder; serotonin-noradrenaline reuptake inhibitor; social anxiety disorder; specific phobia; treatment

Mesh:

Substances:

Year:  2014        PMID: 24713617     DOI: 10.1177/0269881114525674

Source DB:  PubMed          Journal:  J Psychopharmacol        ISSN: 0269-8811            Impact factor:   4.153


  125 in total

Review 1.  Human pharmacology of positive GABA-A subtype-selective receptor modulators for the treatment of anxiety.

Authors:  Xia Chen; Joop van Gerven; Adam Cohen; Gabriel Jacobs
Journal:  Acta Pharmacol Sin       Date:  2018-12-05       Impact factor: 6.150

Review 2.  The use of medication in selective mutism: a systematic review.

Authors:  Katharina Manassis; Beate Oerbeck; Kristin Romvig Overgaard
Journal:  Eur Child Adolesc Psychiatry       Date:  2015-11-09       Impact factor: 4.785

3.  Association between suicide death and concordance with benzodiazepine treatment guidelines for anxiety and sleep disorders.

Authors:  Jennifer M Boggs; Richard C Lindrooth; Catherine Battaglia; Arne Beck; Debra P Ritzwoller; Brian K Ahmedani; Rebecca C Rossom; Frances L Lynch; Christine Y Lu; Beth E Waitzfelder; Ashli A Owen-Smith; Gregory E Simon; Heather D Anderson
Journal:  Gen Hosp Psychiatry       Date:  2019-11-17       Impact factor: 3.238

Review 4.  Modulation of the Endocannabinoid and Oxytocinergic Systems as a Potential Treatment Approach for Social Anxiety Disorder.

Authors:  Rafael Guimarães Dos Santos; Flávia de Lima Osório; Rocio Martin-Santos; Antonio Waldo Zuardi; Jaime Eduardo Cecilio Hallak; José Alexandre S Crippa
Journal:  CNS Drugs       Date:  2019-10       Impact factor: 5.749

Review 5.  Anxiety Disorders and Obsessive-Compulsive Disorder in Individuals with Autism Spectrum Disorder.

Authors:  Valentina Postorino; Connor M Kerns; Giacomo Vivanti; Jessica Bradshaw; Martina Siracusano; Luigi Mazzone
Journal:  Curr Psychiatry Rep       Date:  2017-10-30       Impact factor: 5.285

Review 6.  The Walking Wounded: Emerging Treatments for PTSD.

Authors:  Durga Bestha; Layla Soliman; Kelly Blankenship; James Rachal
Journal:  Curr Psychiatry Rep       Date:  2018-09-14       Impact factor: 5.285

7.  Error-related Brain Activity as a Treatment Moderator and Index of Symptom Change during Cognitive-Behavioral Therapy or Selective Serotonin Reuptake Inhibitors.

Authors:  Stephanie M Gorka; Katie L Burkhouse; Heide Klumpp; Amy E Kennedy; Kaveh Afshar; Jennifer Francis; Olusola Ajilore; Scott Mariouw; Michelle G Craske; Scott Langenecker; Stewart A Shankman; K Luan Phan
Journal:  Neuropsychopharmacology       Date:  2017-11-28       Impact factor: 7.853

8.  Protective effect of propranolol and nadolol on social defeat-induced behavioral impairments in rats.

Authors:  Safiyya Zaidi; Fatin Atrooz; Daniel Valdez; Hesong Liu; Camila Kochi; Richard A Bond; Samina Salim
Journal:  Neurosci Lett       Date:  2020-03-09       Impact factor: 3.046

9.  The Efficacy of a Group CBT Relapse Prevention Program for Remitted Anxiety Disorder Patients Who Discontinue Antidepressant Medication: A Randomized Controlled Trial.

Authors:  Willemijn D Scholten; Neeltje M Batelaan; Patricia van Oppen; Johannes H Smit; Adriaan W Hoogendoorn; Harold J G M van Megen; Daniëlle C Cath; Anton J L M van Balkom
Journal:  Psychother Psychosom       Date:  2018-06-01       Impact factor: 17.659

10.  Long-term antidepressant use: a qualitative study on perspectives of patients and GPs in primary care.

Authors:  Renske C Bosman; Klaas M Huijbregts; Peter Fm Verhaak; Henricus G Ruhé; Harm Wj van Marwijk; Anton Jlm van Balkom; Neeltje M Batelaan
Journal:  Br J Gen Pract       Date:  2016-08-15       Impact factor: 5.386

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.